Health Canada Issues a Foreign
July 6, 2006
Health Canada is advising consumers
not to use Fat Rapid Loss Capsules (Xin Yan Zi
Pai Mei Zi Jiao Nang), made by Shangxi Fei-Te
Biotechnology Inc. in China. Fat Rapid Loss Capsules
are marketed as a weight loss product. The capsules
are dark blue in colour and contained in silver
and blue blister packs.
On June 8, 2006 the Hong Kong Department
of Health advised the public not to use this weight
loss product because it is adulterated with sibutramine.
Sibutramine is a prescription medication used
to suppress appetite, and should only be taken
under the guidance of a health care professional.
Use of sibutramine may cause serious
side effects, including vision problems and increased
heart rate and blood pressure. Sibutramine should
not be taken with medications that can affect
the level of serotonin in the brain, such as antidepressants.
No adverse reactions related to this product have
been reported through the Canadian Adverse Drug
Reaction Monitoring Program.
These products are not authorized for sale in
Canada and have not been found in the Canadian
marketplace. However, it is possible these products
could be purchased by Canadians travelling abroad
or have been brought into Canada through personal
importation by travellers or purchased over the
Canadians who have these products
are advised not to use them, and should consult
with a health care professional if they have concerns
about their health related to the use of these
Drugs and natural health products
that are authorized for sale in Canada will have
either an eight-digit Drug Identification Number
(DIN), a Natural Product Number (NPN) or a Homeopathic
Medicine Number (DIN-HM) on the label. These numbers
indicate that the products have been assessed
by Health Canada for safety, effectiveness and
Health Canada advises Canadians
to contact the Health Products and Food Branch
Inspectorate at 1-800-267-9675 if they find any
of the products listed in the table in the Canadian
For more information about the information
contained in this advisory, please contact Health
Canada’s public enquiries line at (613)
957-2991 or toll-free at 1-866-225-0709.
To report a suspected adverse reaction,
please visit the MedEffect
Adverse Reaction Reporting page.